Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -42.84% is 46% below its 5-year average of -29.34%, around the middle of its 5-year range (-72.53%–-9.54%).
179.82% below its 12-month average of -15.31%.
Reported quarterly return on assets; no daily interpolation. Q1 FY2027 (2026-06-30): -31.53%.
RETURN ON ASSETS (ROA)
-42.84%
RETURN ON ASSETS (ROA) AVG TTM
-15.31%
RETURN ON ASSETS (ROA) AVG 3Y
-31.73%
RETURN ON ASSETS (ROA) AVG 5Y
-29.34%
RETURN ON ASSETS (ROA) AVG 10Y
-57.57%
RETURN ON ASSETS (ROA) AVG 15Y
-40.56%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-179.82%
CURRENT VS 3Y AVG
-34.99%
CURRENT VS 5Y AVG
-46.00%
CURRENT VS 10Y AVG
+25.58%
CURRENT VS 15Y AVG
-5.62%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-32.88%
vs the sector median at left
Grace Therapeutics, Inc.
Market Cap
$34.26M
Return on Assets (ROA)
-42.84%
TTM Avg
-15.31%
3Y Avg
-31.73%
5Y Avg
-29.34%
Market Cap
$34.48M
Return on Assets (ROA)
118.69%
TTM Avg
-31.86%
3Y Avg
-49.56%
5Y Avg
-43.59%
Market Cap
$33.63M
Return on Assets (ROA)
-176.33%
TTM Avg
-88.31%
3Y Avg
-79.12%
5Y Avg
-81.37%
Market Cap
$35.28M
Return on Assets (ROA)
-136.91%
TTM Avg
-90.70%
3Y Avg
-79.79%
5Y Avg
-214.88%
Market Cap
$33.10M
Return on Assets (ROA)
-11.09%
TTM Avg
-5.71%
3Y Avg
-4.17%
5Y Avg
-3.19%
Market Cap
$35.60M
Return on Assets (ROA)
-103.00%
TTM Avg
-39.81%
3Y Avg
-17.36%
5Y Avg
-12.69%
Market Cap
$33.34M
Return on Assets (ROA)
-39.14%
TTM Avg
-11.59%
3Y Avg
6.23%
5Y Avg
18.56%
Market Cap
$32.92M
Return on Assets (ROA)
-114.53%
TTM Avg
-107.26%
3Y Avg
-84.46%
5Y Avg
-72.21%
Market Cap
$33.18M
Return on Assets (ROA)
-190.81%
TTM Avg
-476.65%
3Y Avg
-339.92%
5Y Avg
-580.90%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $34.26M | -42.84% | -15.31% | -31.73% | -29.34% |
| Elutia Inc (ELUT)vs › | $34.48M | 118.69% | -31.86% | -49.56% | -43.59% |
| Scilex Holding Company (SCLX)vs › | $33.63M | -176.33% | -88.31% | -79.12% | -81.37% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.28M | -136.91% | -90.70% | -79.79% | -214.88% |
| Accuray Incorporated (ARAY)vs › | $33.10M | -11.09% | -5.71% | -4.17% | -3.19% |
| DocGo Inc. (DCGO)vs › | $35.60M | -103.00% | -39.81% | -17.36% | -12.69% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $33.34M | -39.14% | -11.59% | 6.23% | 18.56% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $32.92M | -114.53% | -107.26% | -84.46% | -72.21% |
| HeartBeam, Inc. (BEAT)vs › | $33.18M | -190.81% | -476.65% | -339.92% | -580.90% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.75M | -120.78% | -168.59% | -147.82% | -131.31% |
ROA
-42.8%
ROE
-44.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-03-31 | -11.69% |
| 2025-03-31 | -18.93% |
| 2024-03-31 | -23.79% |
| 2023-03-31 | -72.53% |
| 2022-03-31 | -9.54% |
| 2021-03-31 | -39.58% |
| 2020-03-31 | -157.81% |
| 2019-03-31 | -106.69% |
| 2018-03-31 | -93.66% |
| 2017-03-31 | -41.44% |
| 2016-02-29 | -22.15% |
| 2015-02-28 | -4.45% |
| 2014-02-28 | -25.45% |
| 2013-02-28 | -56.63% |
| 2012-02-29 | -41.33% |
| 2011-02-28 | -27.77% |
| 2010-02-28 | -16.95% |
| 2009-02-28 | -44.31% |
